



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Kling et al.)
Serial No.: 10/049,266 ✓) Group Art Unit: N/A
Filed:)
For: Novel Antagonists of Integrin)
Receptors ✓)
Examiner: N/A)

RECEIVED
JAN 13 2003
TECH CENTER 1600/2900
161 ✓ #8
9/26/03
82 ✓

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Copies of the references are enclosed. Entry into the record is respectfully requested.

Respectfully submitted


By Martin L. Katz ✓
Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
Citicorp Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661-2511
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on **January 6, 2003**.

For Small



Please type a plus sign (+) inside this box →



Comparable to Form PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/049,266
				Filing Date	
				First Named Inventor	Kling et al.
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	2	of	3	Attorney Docket No.	50559

RECEIVED
JAN 13 2003
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	E. Ruoslahti et al., Cell 1986, 44, 517-518	
	✓	E. Ruoslahti et al., Science 1987, 238, 491-497	
	✓	L. Piali et al., J. Cell Biol. 1995, 130, 517-518	
	✓	C. D. Buckley et al., J. Cell Science 1996, 109, 437-445	
	✓	M. L. Kireeva et al., J. Biol. Chem. 1998, 273, 3090-3096	
	✓	E. T. Choi et al., J. Vasc. Surg. 1994, 19, 125-134	
	✓	H. Matsuno et al., Circulation 1994, 90, 2203-2206	
	✓	E. Noiri et al., Kidney Int. 1994, 46, 1050-1058	
	✓	M. S. Goligorsky et al., Proc. Natl. Acad. Sci. 1993, 90, 5700-5704	
	✓	E. Noiri et al., Kidney Int. 1995, 48, 1375-1385	
	✓	P.A. D'Amore et al., Ann. Rev. Physiol 1987, 49, 453-464	
	✓	G. C. Brown et al., Int. Ophthalmol. 1987, 11, 41-50	
	✓	P. C. Brooks et al., Cell 1994, 79, 1157-1164	
	✓	J. Folkman et al., J. Biol. Chem. 1992, 267, 10931-10934	
	✓	L. A. Liotta et al., Cell 1991, 64, 327-336	
		J. Folkman et al., Nature 1989, 339, 58-61	
	✓	M. Friedlander et al., Science 1995, 270, 1500-1502	
	✓	D. T. Denhardt et al., FASEB J. 1993, 7, 1475-1482	
	✓	M. A. Horton et al., Exp. Cell Res. 1991, 195, 368-375	
	✓	M. Aumailley et al., FEBS Letts 1991, 291, 50-54	

	J	M. Pfaff et al., J. Biol. Chem. 1994, 269, 20233-20238	
	✓	D. A. Cheresch et al., J. Biol. Chem. 1987, 262, 17703-17711	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JAN 13 2003

TECH CENTER 1600/2900

